Reference is made to the stock exchange notice published by Hofseth BioCare ASA ("Hofseth BioCare") on 1 March 2013 concerning the issue of 200.000 shares to each of Bomi Framroze and Magne Brauten according to option program.
The share capital increase related to the private placement resolved by the board meeting held 28 February 2013 according to authorization from the general meeting of Hofseth BioCare has now been registered with the Norwegian Register of Business Enterprises.
The share capital of Hofseth BioCare is NOK 70 487 354 divided into 70 487 354 shares, each with a nominal value of NOK 1.
For further information, please contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Tel +47 936 32 966
E-mail: joo@h-bc.no
Øystein Omvik, CFO Hofseth BioCare ASA
Tel: +47 936 99 400
E-mail: oystein.omvik@h-bc.no
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biomarine company with the key objective to provide high value added biomarine ingredients for human applications. The Company is founded on the core value of sustainability and optimal use of natural resources. Through innovative production technology and logistics, Hofseth BioCare is able to preserve the quality of protein, calcium and oil extracted from fish off-cuts. Products that previously could only be used as animal feed can now be made suitable for human consumption. HBCs objective is thus to contribute to efficient use of marine resources and entering the higher profit market of quality ingredients for human applications.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.